| Specialty Retail Industry | Consumer Discretionary Sector | Chen Xin CEO | NASDAQ (CM) Exchange | KYG7307E1237 ISIN |
| CN Country | 298 Employees | - Last Dividend | 21 Jun 2024 Last Split | - IPO Date |
Qilian International Holding Group Limited is recognized for its expertise in manufacturing and distributing a wide range of products within China, particularly in the pharmaceutical sector. Founded in 2019 and headquartered in Jiuquan, People's Republic of China, the company focuses on producing active pharmaceutical ingredients (APIs), derivatives of traditional Chinese medicine (TCMD), and various other by-products. Its product lineup, primarily centered around licorice products and oxytetracycline tablets, caters to both human health and veterinary uses, illustrating the diversity in its manufacturing capabilities.